Insulin-like growth factor binding protein-3: relationship to the development of gastric pre-malignancy and gastric adenocarcinoma (United Kingdom)
| Autor: | Derek Alderson, Roger Feakins, P.B. Savage, Jyoti Gupta, Jeffrey M P Holly, Moganaden Moorghen, Andrew Hollowood, P.V. Newcomb, Zun-Wu Zhang |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Male
Cancer Research medicine.medical_specialty Genotype IGFBP3 Adenocarcinoma Malignancy Polymerase Chain Reaction Insulin-like growth factor-binding protein Stomach Neoplasms Internal medicine Tumor Cells Cultured Humans Medicine RNA Messenger Promoter Regions Genetic Polymorphism Genetic Hematology biology business.industry Intestinal metaplasia Histology DNA Middle Aged medicine.disease Immunohistochemistry United Kingdom Gene Expression Regulation Neoplastic Insulin-Like Growth Factor Binding Protein 3 Endocrinology Oncology Apoptosis biology.protein Female Tumor Suppressor Protein p53 business Precancerous Conditions |
| Zdroj: | Cancer Causes & Control. 15:211-218 |
| ISSN: | 0957-5243 |
| DOI: | 10.1023/b:caco.0000019510.96285.e9 |
| Popis: | IGF family proteins play a pivotal role in regulating cell growth and apoptosis in normal and tumour tissues. IGFBP-3 is the major binding protein of IGFs and modulates the bioactivity of IGFs. To examine the role of IGFBP-3 in gastric cancer, an IGFBP3 promoter polymorphism, and serum and gastric mucosal levels of IGFBP-3 were assessed in two independent groups of patients (396 and 117 patients, respectively) with gastroduodenal diseases. There was no significant association between IGFBP-3 polymorphism and different gastroduodenal diseases ( p = 0.6), but a significantly higher frequency of CC, a genotype related to lower levels of serum IGFBP-3 previously, were observed in patients with antral intestinal metaplasia when compared with those without this pre-malignancy ( p = 0.04). Similarly, data from another independent group of patients further showed that patients with antral or corpus intestinal metaplasia had significantly lower serum levels of IGFBP-3 than those without these changes ( p = 0.03 and 0.04, respectively). Furthermore, the percentage of positive IGFBP-3 staining in tumour tissue was significantly higher in patients with well or moderately differentiated tumours than those with poorly differentiated tumours ( p = 0.04), indicating that IGFBP-3 may be associated with a better prognosis. In conclusion, our study suggests that IGFBP-3 may be protective against the development of gastric adenocarcinoma by preventing the formation of intestinal metaplasia and improve the prognosis of gastric cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink